Precision Biosciences (DTIL) Equity Ratio (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Equity Ratio data on file, last reported at 0.53 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.53, up 33.37% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.53 (up 33.37% YoY), and the FY2025 annual result was 0.6, up 44.48% from the prior year.
• Equity Ratio retreated to 0.53 in Q1 2026 per DTIL's latest filing, from 0.6 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.6 in Q4 2025 and troughed at 0.12 in Q4 2023.
• A 5-year average of 0.32 and a median of 0.31 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio surged 250.28% in 2024, then tumbled 57.97% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.25 in 2022, then sank by 53.48% to 0.12 in 2023, then surged by 250.28% to 0.41 in 2024, then soared by 44.48% to 0.6 in 2025, then declined by 11.47% to 0.53 in 2026.
• Business Quant data shows DTIL's Equity Ratio at 0.53 in Q1 2026, 0.6 in Q4 2025, and 0.18 in Q3 2025.